Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma

Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma

Publication date: Apr 12, 2019

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. , a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the DecisionDx(R)-Melanoma gene expression profile (GEP) test accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node biopsy (SLNB) result.

The study was published in the journal Cancer Medicine and is consistent with previously published prospective and retrospective studies demonstrating the high performance of DecisionDx-Melanoma to predict outcomes, supporting its clinical value to inform patient management decisions.

DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors and has been studied in over 2,900 patients.

The consistent high performance and accuracy demonstrated in these studies, which combined have included over 1,470 patients, provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results.

The Company currently offers tests for patients with cutaneous melanoma (DecisionDx(R)-Melanoma, DecisionDx(R)-CMSeq; www. SkinMelanoma. com) and uveal melanoma (DecisionDx(R)-UM, DecisionDx(R)-PRAME and DecisionDx(R)-UMSeq; www. MyUvealMelanoma. com), with programs in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma.

Concepts Keywords
Adjuvant Therapy PRAME
AJCC Uveal melanoma
Arizona Sentinel lymph node
BUSINESS WIRE Lymph node biopsy
Friendswood Breslow’s depth
FRIENDSWOOD RTT
General Surgery Cancer staging
Houston Medicine
Melanoma Clinical medicine
Metastasis Medical specialties
Phoenix Melanoma
Risk Assessment Adjuvant therapy
Sentinel Lymph Node Individual patients tumor
Squamous Carcinoma High DecisionDx Melanoma
Surveillance Risk melanoma
Texas Cutaneous melanoma metastasis
Tumor Tumor
Ulcerated Patients confidence management
Uveal Melanoma Cancers

Semantics

Type Source Name
disease MESH squamous cell carcinoma
disease MESH development
gene UNIPROT PRAME
disease DOID uveal melanoma
disease MESH uveal melanoma
drug DRUGBANK Coenzyme M
gene UNIPROT IMPACT
disease MESH metastasis
disease MESH recurrence
gene UNIPROT GRN
pathway BSID Gene Expression
gene UNIPROT GNA12
disease DOID cancer
drug DRUGBANK Nonoxynol-9
disease MESH cancer
gene UNIPROT WIPF2
disease MESH skin cancer
disease DOID skin cancer
pathway BSID Melanoma
disease DOID Cutaneous Melanoma
disease DOID Melanoma
disease MESH Melanoma
disease DOID squamous cell carcinoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *